Welcome to the The Department of Oncology. The Department of Oncology's mission is to improve cancer care through research and teaching. There is strong emphasis on translation, with established infrastructure to develop scientific insights toward clinical appreciation.
The Department houses over 400 staff and postgraduate students - both clinical and non-clinical - and is one of the largest departments in the University of Oxford's Medical Sciences Division.
One of the key aims for the Department is to bring together basic scientific and clinical research groups from across Oxford - based in the Old Road Campus Research Building, the Radiobiology Research Institute, the Weatherall Institute for Molecular Medicine and the NHS Cancer and Haematology Centre - to apply knowledge of cancer and to develop research so that we may better understand how we can combat cancer in the most effective way possible.
The Howat Foundation to fund Chair in Clinical Oncology
10 May 2023
Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation
New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years
6 April 2023
A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.
Mark Hill becomes Fellow of the Institute of Physics and Engineering in Medicine
16 March 2023
Dr Mark Hill was awarded the honour of Fellow of the Institute of Physics and Engineering in Medicine (FIPEM) after ‘demonstrating scientific and professional attainment of outstanding merit’.
Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment
16 December 2022
New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.